Targeted Therapy Opportunity Casma Therapeutics focuses on lysosomal and autophagy pathways to degrade disease targets, presenting a sales opening for partners or vendors offering niche assay services, biomarker panels, or high-content screening compatible with autophagy and lysosomal biology.

Parkinson's Expansion Lead program CSM-101 targets Parkinson's disease and Gaucher’s disease, signaling opportunities for strategic collaborations, CRO support in translational studies, and access to CNS-targeted delivery platforms or biomarker development for PD.

PHLYTTM Platform The PHLYTTM selective autophagy degraders platform suggests demand for collaborations around degradation biology analytics, target engagement assays, and technologies enabling large complex target degradation (organelle and protein aggregates).

Funding Momentum Recent MJFF funding and multi-million grants indicate a validated program risk profile and potential for co-sponsorship or grant-aligned partnerships, plus interest from Parkinson’s focused investors and institutions.

Signal to Scale With a modest headcount (11-50) and a substantial funding base, Casma may seek tools, services, and strategic advisory to accelerate preclinical to IND timelines, including translational services, regulatory strategy support, and GMP-readiness planning.